Growth inhibitory effects of transforming growth factor-beta 1 in vivo

¹Department of Experimental Haematology, Paterson Institute for Cancer Research, Manchester, England.

|January 1, 1991

Abstract:

Transforming growth factor-beta (TGF-beta) can reversibly inhibit the in vitro proliferation of murine and human haemopoietic progenitors and some of their more developmentally restricted progeny. Using an assay for measuring day 8 and day 11 CFU-S, TGF-beta caused a gradual decline in the number of CFU-S undergoing DNA synthesis so that after 5 days of daily treatment only quiescent cells were found. Release of this growth inhibition was seen within 24 hours post-treatment with recovery of all progenitors to normal levels. Similar inhibitory effects of TGF-beta were seen on the cells of the intestinal epithelium, indicating that TGF-beta is a general stem cell growth inhibitor. These results suggest that TGF-beta can be used as a cytostatic agent to protect normal stem cells in patients being treated with cell cycle-specific cytotoxic agents.

Related Experiment Videos

Growth inhibitory effects of transforming growth factor-beta 1 in vivo

Related Concept Videos

Mathematical modelling of contact dermatitis from nickel and chromium.

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

Myelofibrosis patients in Belgium: disease characteristics.

Systematic review of respiratory case definitions in metalworking fluid outbreaks.

Haemopoietic growth factors: their role in cell development and their clinical use.

Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.

Effects of aging in combination with high-fat or ketogenic diet on skeletal muscle hypertrophy after functional overloading in C57BL/6J mice.

BMP7 peripheral sequence evolution correlates with mammalian cloacal septation.

The role of the epidermal growth factor in the pathogenesis of schizophrenia. Clinical and diagnostic value.

The role of ERK signaling pathway in pituitary adenomas: from molecular mechanisms to targeted therapy.

Role of soluble EGFR, Fas, and Fas ligand in pelvic pain severity and their association with endometriosis in infertile woman: a case-control study.

ErbB receptor stimulation is required for mouse Colon adenoma organoids to form crypts.

Co-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.

Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.

Related Experiment Videos

Growth inhibitory effects of transforming growth factor-beta 1 in vivo

Abstract:

Related Concept Videos

Related Articles